Clinicopathological characteristics and expression of ER, PR, HER2, HIF-1α, CAIX and Glut-1 in DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.

<p>Clinicopathological characteristics and expression of ER, PR, HER2, HIF-1α, CAIX and Glut-1 in DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.</p

Correlation of HIF-1α expression in DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers with age, grade, ER, PR, HER2, CAIX and Glut-1 expression in these lesions.

<p>Correlation of HIF-1α expression in DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers with age, grade, ER, PR, HER2, CAIX and Glut-1 expression in these lesions.</p

Correlation of HIF-1α, CAIX and Glut-1 between invasive and DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.

<p>Correlation of HIF-1α, CAIX and Glut-1 between invasive and DCIS lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.</p

Immunohistochemical staining of HIF-1α, CAIX and Glut-1 in normal breast tissue (A, D and G), DCIS (B, E and H) and concomitant invasive cancer (C, F and I) of a <i>BRCA1</i> mutation carrier.

<p>Immunohistochemical staining of HIF-1α, CAIX and Glut-1 in normal breast tissue (A, D and G), DCIS (B, E and H) and concomitant invasive cancer (C, F and I) of a <i>BRCA1</i> mutation carrier.</p

Clinicopathological characteristics and expression of ER, PR, HER2, HIF-1α, CAIX and Glut-1 in DCIS and accompanying invasive lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.

<p>Clinicopathological characteristics and expression of ER, PR, HER2, HIF-1α, CAIX and Glut-1 in DCIS and accompanying invasive lesions of <i>BRCA1</i>, <i>BRCA2</i> and non-<i>BRCA</i> mutation carriers.</p

p-values of association (−log10 scale) with breast cancer risk in <i>BRCA2</i> carriers for genotyped and imputed SNPs in the <i>NEIL2</i> gene.

<p>SNP rs1466785 is indicated with a purple arrow and the best causal imputed SNPs, rs804276 and rs804271 are indicated with a red arrow. Colors represent the pariwise r². Plot generated with LocusZoom <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1004256#pgen.1004256-Pruim1" target="_blank">[42]</a> (<a href="http://csg.sph.umich.edu/locuszoom/" target="_blank">http://csg.sph.umich.edu/locuszoom/</a>).</p

Associations with breast and ovarian cancer risk for SNPs observed at p-trend<0.05 in stage II of the experiment.

a<p>Hazard Ratio per allele (1 df) estimated from the retrospective likelihood analysis.</p>b<p>Hazard Ratio under the genotype specific models (2df) estimated from the retrospective likelihood analysis.</p>c<p>p-values were based on the score test.</p>d<p>HR per allele of 1.69 and p-trend of 1×10⁻⁴ for <i>BRCA2</i> mutation carriers in stage I of the study.</p>e<p>HR per allele of 1.43 and p-trend of 0.01 for <i>BRCA1</i> mutation carriers in stage I of the study.</p>f<p>HR per allele of 1.30 and p-trend of 0.03 for <i>BRCA1</i> mutation carriers in stage I of the study.</p>g<p>HR per allele of 0.64 and p-trend of 0.057 for <i>BRCA2</i> mutation carriers in stage I of the study.</p>h<p>HR per allele of 1.25 and p-trend of 0.04 for <i>BRCA1</i> mutation carriers in stage I of the study.</p>i<p>HR per allele of 1.25 and p-trend of 0.058 for <i>BRCA2</i> mutation carriers in stage I of the study.</p>j<p>rs3093926 did not yield results under the genotype specific model due to the low minor allele frequency.</p><p>Complete description of results from stage I are included in Supplementary <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1004256#pgen.1004256.s002" target="_blank">Table S1</a>.</p><p>Highlighted in bold are those SNPs showing strongest associations with breast or ovarian cancer risk (p<0.01).</p

The <i>HMMR</i> locus and breast cancer risk in <i>BRCA1</i> mutation carriers.

<p>(<b>A</b>) Forest plots showing rs299290 HRs and 95% CIs (retrospective likelihood trend estimation) for participating countries (relatively small sample sets are not shown) ordered by sample size. Left and right panels show results for <i>BRCA1</i> and <i>BRCA2</i> mutation carriers, respectively. The sizes of the rectangles are proportional to the corresponding country/study precision. (<b>B</b>) The rs299290-containing region, including the genes, variation and regulatory evidence mentioned in HMECs. Exons are marked by black-filled rectangles and the direction of transcription is marked by arrows in the genomic structure. The chromosome 5 positions (base pairs (bp)) and linkage disequilibrium structure from Caucasian HapMap individuals are also shown.</p

Gene expression interactions in breast cancer survival.

<p>(<b>A</b>) Kaplan–Meier survival curves based on categorization of <i>HMMR</i> (probe NM_012484) and <i>AURKA</i> (NM_003600) expression in tertiles (low, medium or high expression). For simplicity, only the tertiles for “high” <i>AURKA</i> are shown. The tumours with high expression levels for both genes were not those with the poorest prognosis. (<b>B</b>) Kaplan–Meier survival curves based on categorization of <i>HMMR</i> (NM_012484) and <i>TUBG1</i> (NM_016437) expression in tertiles (low, medium or high expression). For simplicity, only the tertiles for “high” <i>HMMR</i> are shown. The cases with high expression levels for both genes were those with the poorest prognosis.</p

Potential GxG associated with breast cancer risk in <i>BRCA1/2</i> mutation carriers.

<p>*Each estimate is derived from the interaction term of a Cox regression model.</p><p>Potential GxG associated with breast cancer risk in <i>BRCA1/2</i> mutation carriers.</p